Rosenbach M

No ORCID on file · 2 papers in corpus
2020
Drugs in R&D ·doi:10.1007/s40268-020-00311-6

The prevalence of cutaneous adverse events attributable to newly approved anti-cancer drugs has been well reviewed in the dermatologic literature. In contrast, over 75% of US Food and Drug Administration approvals in the past 5 years have b…

2018
The journal of allergy and clinical immunology. In practice ·doi:10.1016/j.jaip.2017.11.023

Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a life-threatening, immunologically mediated, and usually drug-induced disease with a high burden to individuals, their families, and society with an annual incidence of 1 to …